Clinical Trial Update: Study of Combined VisioCyt Test and FGFR3 Mutations on a Urinary Sample to Diagnose Bladder Tumors [NA]

View source ↗

Summary

A completed clinical trial evaluating a combined VisioCyt urinary test and FGFR3 mutation analysis to diagnose bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Snippet

Sponsor: Institut de Cancérologie de Lorraine | Conditions: Bladder Cancer | NA | Status: COMPLETED